GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Sun-Novo Pharmaceutical Research Co Ltd (SHSE:688621) » Definitions » COGS-to-Revenue

Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) COGS-to-Revenue : 0.53 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Beijing Sun-Novo Pharmaceutical Research Co COGS-to-Revenue?

Beijing Sun-Novo Pharmaceutical Research Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥123 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥231 Mil.

Beijing Sun-Novo Pharmaceutical Research Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Beijing Sun-Novo Pharmaceutical Research Co's Gross Margin % for the three months ended in Mar. 2025 was 46.57%.

Beijing Sun-Novo Pharmaceutical Research Co COGS-to-Revenue Historical Data

The historical data trend for Beijing Sun-Novo Pharmaceutical Research Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Sun-Novo Pharmaceutical Research Co COGS-to-Revenue Chart

Beijing Sun-Novo Pharmaceutical Research Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial 0.50 0.47 0.45 0.43 0.50

Beijing Sun-Novo Pharmaceutical Research Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.47 0.54 0.61 0.53

Beijing Sun-Novo Pharmaceutical Research Co COGS-to-Revenue Calculation

Beijing Sun-Novo Pharmaceutical Research Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=537.334 / 1078.474
=0.50

Beijing Sun-Novo Pharmaceutical Research Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=123.339 / 230.84
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Sun-Novo Pharmaceutical Research Co  (SHSE:688621) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Beijing Sun-Novo Pharmaceutical Research Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 123.339 / 230.84
=46.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Beijing Sun-Novo Pharmaceutical Research Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Beijing Sun-Novo Pharmaceutical Research Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Sun-Novo Pharmaceutical Research Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Sun-Novo Pharmaceutical Research Co Ltd (SHSE:688621) » Definitions » COGS-to-Revenue
Comparable Companies
SZSE:301277 SZSE:002424 SZSE:301393 BJSE:830946 SZSE:002907 SZSE:301246 SZSE:002437 SZSE:002581 SHSE:600976 SZSE:002349 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
No. 79 Shuangying West Road, 1st Floor, Building 7, Science Park, Changping District, Beijing, CHN, 102200
Website
http://www.sun-novo.com
Beijing Sun-Novo Pharmaceutical Research Co Ltd is engaged in providing professional research and development outsourcing services for pharmaceutical companies.
Executives
Liu Yu Jing Directors, senior managers
Shao Yan Director
Zhao Ling Yang Director
Li Qian Director

Beijing Sun-Novo Pharmaceutical Research Co Headlines

No Headlines